公开(公告)号：US11406633B2

公开(公告)日：2022-08-09

申请号：US16482836

申请日：2018-02-12

Applicant: Novartis AG

Inventor： Jason Russell Dobson ,  Susan Moody ,  Margaret Elise McLaughlin

IPC: A61K31/497 ,  A61P35/00 ,  A61K9/00 ,  C07K16/28

Abstract: The present disclosure relates to the field of pharmacy, particularly to a Wnt inhibitor and a PD-1 inhibitor for use in the treatment of cancer. Specifically, the disclosure relates to a pharmaceutical combination comprising a Wnt inhibitor, or a pharmaceutically acceptable salt thereof, and a PD-1 inhibitor, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer, to a method for the treatment of cancer that involves administering the combination and to the use of the combination for the manufacture of a medicament for the treatment of cancer.

公开(公告)号：US20230063366A1

公开(公告)日：2023-03-02

申请号：US17809623

申请日：2022-06-29

Applicant: NOVARTIS AG

Inventor： Jason Russell Dobson ,  Susan Moody ,  Margaret Elise McLaughlin

IPC: A61K31/497 ,  A61P35/00 ,  A61K9/00 ,  C07K16/28

Abstract: The present disclosure relates to the field of pharmacy, particularly to a Wnt inhibitor and a PD-1 inhibitor for use in the treatment of cancer. Specifically, the disclosure relates to a pharmaceutical combination comprising a Wnt inhibitor, or a pharmaceutically acceptable salt thereof, and a PD-1 inhibitor, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer, to a method for the treatment of cancer that involves administering the combination and to the use of the combination for the manufacture of a medicament for the treatment of cancer.